EraCal Therapeutics enters agreement with Novo Nordisk including milestones payment up to EUR 235 million
23.01.2024
The agreement marks a crucial step in the joint efforts of the two companies to develop and commercialize EraCal's oral, small molecule program, as it holds the potential to reshape the landscape of obesity treatment.
 EraCal COO Simon Breitler and CEO Josua Jordi
|
 |
Novo Nordisk, the European giant in obesity therapy, has entered an exclusive collaboration with EraCal Therapeutics. Novo Nordisk now holds exclusive rights to develop and commercialize EraCal's oral, small molecule program—a potential game-changer in obesity treatment.
As the market leader in obesity therapy and the largest European company by market cap, Novo Nordisk's strategic move further solidifies its dominance. EraCal stands to gain significantly, with upfront, development and commercial milestones totalling up to EUR 235 million, along with ongoing royalties on sales of any marketed product resulting from the collaboration.
Josua Jordi, CEO of EraCal Therapeutics, sees this as a validation of EraCal's platform technology and a commitment to pioneering approaches in obesity therapy. The alliance promises to bring innovative solutions to the global challenge of obesity, marking a significant leap forward in therapeutic options for those affected.
EraCal participated in Venture Leaders Life Sciences in 2020, won the last stage of Venture Kick in 2019, and was ranked among the TOP 100 Swiss Startups from 2020 to 2023.
EraCal COO Simon Breitler and CEO Josua Jordi
As the market leader in obesity therapy and the largest European company by market cap, Novo Nordisk's strategic move further solidifies its dominance. EraCal stands to gain significantly, with upfront, development and commercial milestones totalling up to EUR 235 million, along with ongoing royalties on sales of any marketed product resulting from the collaboration.
Josua Jordi, CEO of EraCal Therapeutics, sees this as a validation of EraCal's platform technology and a commitment to pioneering approaches in obesity therapy. The alliance promises to bring innovative solutions to the global challenge of obesity, marking a significant leap forward in therapeutic options for those affected.
EraCal participated in Venture Leaders Life Sciences in 2020, won the last stage of Venture Kick in 2019, and was ranked among the TOP 100 Swiss Startups from 2020 to 2023.
EraCal COO Simon Breitler and CEO Josua Jordi